"Our Centre of Excellence for External Drug Discovery plays an important role in seeking out highly innovative and transformative science, and capturing a diversity of ideas and talents outside our organization. This is a key element of our strategy to externalize R&D." Moncef Slaoui, Chairman of R&D, GSK

At GlaxoSmithKline (GSK) a specialized R&D business unit is driving growth in external drug discovery to complement the late-stage GSK pipeline. The Center of Excellence for External Drug Discovery (CEEDD) builds and personally manages unique risk/reward-sharing drug discovery alliances with world class biotech companies. We work directly with these companies to bring programs from target to clinical proof of concept, at which stage GSK has options to license for full development and commercialization. As a small, multidisciplinary team, we share our alliance companies’ entrepreneurial spirit and agility, and complement their capabilities with broad expertise and access to big pharma resources to bring innovative new medicines to more patients more quickly.